Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2010. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of insider share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by eight individuals (Mr A P Witty, Mr J S Heslop, Mr S M Bicknell, Mr E J Gray, Mr S A Hussain, Mr D Learmouth, Mr D S Redfern, and Ms C Thomas) on June 9, 2010. Each individual acquired 11 shares through the personal contribution element and 11 shares through the company matching element of the Share Reward Plan. The transaction price was £11.53 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the share purchases described above.
Investor Verification Points
- Verify the share price of £11.53 per Ordinary share on June 9, 2010.
- Confirm the total number of shares acquired by each listed director (22 shares per person: 11 personal, 11 matched).
- Review the terms of the Company's Share Reward Plan to understand the matching contribution structure.
- Note that this filing does not contain financial results; refer to Form 20-F for comprehensive financial data.